In previously untreated patients

In combined results of two clinical trials with REBETRON Combination Therapy, 40 percent of patients who were treated with 48 weeks of REBETRON Combination Therapy had undetectable virus levels as compared to 15 percent of patients who were treated with 48 weeks of INTRON^®A alone. (Please refer to Prescribing Information.)

In patients treated with interferon who have relapsed following treatment

In combined results of two clinical trials with REBETRON Combination Therapy, 46 percent of patients who were treated with 24 weeks of REBETRON Combination Therapy had undetectable virus levels as compared to 5 percent of patients who were treated with 24 weeks of INTRON^®A alone. (Please refer to Prescribing Information.)

Ninety–four percent of the relapse chronic hepatitis C patients who took part in clinical trials for REBETRON Combination Therapy completed their course of therapy.